Paul Tudor Jones's ABCL Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 1.8 M shares of AbCellera Biologics Inc. (ABCL) worth $6.14 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ABCL, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 1.07 M shares. Largest reduction occurred in Q3 2024, reducing 236,649 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's AbCellera Biologics (ABCL) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbCellera Biologics (ABCL) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +79,724 | New Buy | 79,724 | $22.00 |
| Q3 2021 | -64,603 | Reduce 81.03% | 15,121 | $20.04 |
| Q4 2021 | -15,121 | Sold Out | 0 | $0.00 |
| Q1 2022 | +21,109 | New Buy | 21,109 | $9.76 |
| Q2 2022 | -10,840 | Reduce 51.35% | 10,269 | $10.61 |
| Q3 2022 | +4,977 | Add 48.47% | 15,246 | $9.90 |
| Q4 2022 | +402 | Add 2.64% | 15,648 | $0.01 |
| Q1 2023 | +2,424 | Add 15.49% | 18,072 | $0.01 |
| Q2 2023 | +175 | Add 0.97% | 18,247 | $6.46 |
| Q3 2023 | +1,858 | Add 10.18% | 20,105 | $4.60 |
| Q4 2023 | -20,105 | Sold Out | 0 | $0.00 |
| Q1 2024 | +90,734 | New Buy | 90,734 | $4.53 |
| Q2 2024 | +145,915 | Add 160.82% | 236,649 | $2.96 |
| Q3 2024 | -236,649 | Sold Out | 0 | $0.00 |
| Q3 2025 | +730,122 | New Buy | 730,122 | $5.03 |
| Q4 2025 | +1.07 M | Add 145.99% | 1.8 M | $3.42 |
Paul Tudor Jones's AbCellera Biologics Investment FAQs
Paul Tudor Jones first purchased AbCellera Biologics Inc. (ABCL) in Q2 2021, acquiring 79,724 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held AbCellera Biologics Inc. (ABCL) for 16 quarters since Q2 2021.
Paul Tudor Jones's largest addition to AbCellera Biologics Inc. (ABCL) was in Q4 2025, adding 1,796,010 shares worth $6.14 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 1,796,010 shares of AbCellera Biologics Inc. (ABCL), valued at approximately $6.14 M.
As of the Q4 2025 filing, AbCellera Biologics Inc. (ABCL) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in AbCellera Biologics Inc. (ABCL) was 1,796,010 shares, as reported at the end of Q4 2025.